Back    Zoom +    Zoom -
<Research> CLSA: WuXi AppTec (02359.HK) Delivers Strong 1Q26 Results, Named Sector Top Pick
Recommend
5
Positive
2
Negative
0
CLSA published a research report stating that WuXi AppTec (02359.HK) delivered strong results for 1Q26. Revenue from continuing operations increased 39% YoY, while adjusted non-IFRS net profit rose 72%. Adjusted non-IFRS net profit margin expanded 9.2 ppts YoY to 37%.

The broker said that among China CRO or CDMO (Contract Research Organization/Contract Development and Manufacturing Organization) players, WuXi AppTec is its top pick and also one of its core holdings in the global healthcare sector. CLSA assigned an "Outperform" rating to WuXi AppTec with a TP of HKD149.3. (sl/u)

Related News JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO (01801.HK), WUXI APPTEC (02359.HK), WUXI XDC (02268.HK), SKB BIO (06990.HK)
Auto-translated by AI
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details

AASTOCKS Financial News